Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with the Agency for Science, Technology and Research (A*STAR) Bioprocessing Technology Institute (BTI) and National University Health System (NUHS), have developed a groundbreaking technology capable of extracting mesenchymal stem cells (MSCs) directly from pure bone marrow – also known as bone marrow aspirate (BMA), a pivotal source of MSCs – without dilution.
Recent Posts
- UCLA researchers receive $13.9 million CIRM grant to identify drug targets for autism and schizophrenia using human stem cell models
- After allogeneic transplant, VIC-1911 regimen shows low severe GVHD and no relapse
- Nobel Prize winners face new loss in bid for US CRISPR patents
- U.S. judge upends Kennedy’s overhaul of childhood vaccine policies
- Cells can sense 10x farther than expected and it may explain cancer spread


